This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
Questions about our CME?
Questions about our CME?

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Contemporary Management of Type 2 Diabetes

Contemporary Management of Type 2 Diabetes

Format

Slide Lecture Series

Time to Complete

1 hour

Released

February 2, 2018

Expires

February 2, 2019
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider



Provided by Penn State College of Medicine

Commercial Supporter

This activity is supported by an educational grant from Sanofi US.

Program Description

The management of type 2 diabetes (T2D) remains a clinical challenge as patients continue to struggle with achieving therapeutic goals. While there are many treatment options for T2D, there is relatively limited guidance on selection of second- and third-line treatments. This activity will review the most recent T2D treatment guidelines (including strategies for patient communication), and address incretin therapies and their role as monotherapy and in combination with other agents in the management of T2D.

Intended Audience

This educational activity is designed for primary care physicians, nurse practitioners, PAs, nurses, and others who care for patients with T2D.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Review current treatment guidelines for managing T2D.
  • Outline the mechanisms of action of major classes of diabetes medications.
  • Discuss the therapeutic role of incretin-based therapies, alone or in combination with conventional treatments, in the management of T2D.
  • Incorporate recently approved fixed-ratio combination injectables into treatment plans for patients with T2D.
  • Outline recommended strategies and goals for clinician/patient communication about the management of T2D.

Conflict Of Interest Disclosure Policy

It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.

Faculty

Serena Cardillo, MD
Associate Professor of Clinical Medicine
Associate Program Director, Internal Medicine Residency
Division of Endocrinology, Diabetes, and Metabolism
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Dr. Cardillo has nothing to disclose.

John J. Russell, MD
Director, Family Medicine Residency Program
Abington Memorial Hospital
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel College of Medicine
Philadelphia, PA

Dr. Russell has disclosed the following:
Consultant/advisor and speakers bureau: Sanofi Pasteur

Accredited Provider Disclosure

Penn State staff involved in the development and review of this activity have nothing to disclose.

Publishing Staff Disclosures

MCM Education staff involved in the development and review of this activity have nothing to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Penn State College of Medicine designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclaimer

The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Penn State College of Medicine, or Sanofi US. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

Instructions

To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

For questions regarding CME credit, contact Penn State Continuing Education at 717-531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6235-18-T.
Add to Queue